TMCnet News
Research and Markets: Melanoma Drug Pipeline Update 2015 - 274 Companies Plus Partners Developing 310 Drugs Targeting Melanoma in DevelopmentResearch and Markets (http://www.researchandmarkets.com/research/tr37q4/melanoma_drug) has announced the addition of the "Melanoma Drug Pipeline Update 2015" report to their offering. Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%. There are today 274 companies plus partners developing 310 drugs targeting melanoma in development. In addition, there are 2 suspended drugsand the accumulated number of ceased drugs over the last years amount to another 154 drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 274 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 257 out of the 260 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
Delivery Format: Desktop App plus Online Access to Updates (One Year) For more information visit http://www.researchandmarkets.com/research/tr37q4/melanoma_drug |
